Short-course hormonal therapy and the risk of death from prostate cancer in men with intermediate-risk prostate cancer undergoing high-dose radiation therapy

被引：0
|
作者：
Keane, Florence K.
Chen, Ming-Hui
Zhang, Danjie
Moran, Brian Joseph
Braccioforte, Michelle H.
D'Amico, Anthony Victor
机构：
[1] Brigham & Womens Hosp, Harvard Radiat Oncol Program, Boston, MA 02115 USA
[2] Univ Connecticut, Storrs, CT USA
[3] Prostate Canc Fdn Chicago, Westmont, IL USA
[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.27
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
27
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Comorbidity and androgen deprivation therapy use in men undergoing high-dose radiation for unfavorable intermediate- and high-risk prostate cancer.
    Dyer, Michael A.
    Chen, Ming-Hui
    Braccioforte, Michelle H.
    Moran, Brian Joseph
    D'Amico, Anthony V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [22] Race and the Risk of Death Following High-Dose Radiation Therapy in Men Treated With or Without Androgen Suppression Therapy for Favorable-Risk Prostate Cancer
    Kovtun, K.
    Chen, M. H.
    Braccioforte, M. H.
    Moran, B. J.
    D'Amico, A. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E402 - E402
  • [23] Management of high-risk prostate cancer: Radiation therapy and hormonal therapy
    Nomiya, Takuma
    Tsuji, Hiroshi
    Toyama, Shingo
    Maruyama, Katsuya
    Nemoto, Kenji
    Tsujii, Hirohiko
    Kamada, Tadashi
    CANCER TREATMENT REVIEWS, 2013, 39 (08) : 872 - 878
  • [24] Re: Risk Group and Death from Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-Risk Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2016, 196 (02): : 412 - 413
  • [25] Re: Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-risk Prostate Cancer
    Gandaglia, Giorgio
    Briganti, Alberto
    Montorsi, Francesco
    EUROPEAN UROLOGY, 2016, 69 (02) : 370 - 370
  • [26] Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
    Ju, Andrew W.
    Wang, Hongkun
    Oermann, Eric K.
    Sherer, Benjamin A.
    Uhm, Sunghae
    Chen, Viola J.
    Pendharkar, Arjun V.
    Hanscom, Heather N.
    Kim, Joy S.
    Lei, Siyuan
    Suy, Simeng
    Lynch, John H.
    Dritschilo, Anatoly
    Collins, Sean P.
    RADIATION ONCOLOGY, 2013, 8
  • [27] Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study
    Kaplan, Irving
    Bubley, Glenn J.
    Bhatt, Rupal S.
    Taplin, Mary-Ellen
    Dowling, Shanna
    Mahoney, Kathleen
    Werner, E.
    Nguyen, Paul
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (05): : 1416 - 1422
  • [28] Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
    Andrew W Ju
    Hongkun Wang
    Eric K Oermann
    Benjamin A Sherer
    Sunghae Uhm
    Viola J Chen
    Arjun V Pendharkar
    Heather N Hanscom
    Joy S Kim
    Siyuan Lei
    Simeng Suy
    John H Lynch
    Anatoly Dritschilo
    Sean P Collins
    Radiation Oncology, 8
  • [29] Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer
    Yassa, Michael
    Fortin, Bernard
    Fortin, Marie-Andree
    Lambert, Carole
    Nguyen, Thu Van
    Bahary, Jean-Paul
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (01): : 58 - 63
  • [30] Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?
    Shakespeare, Thomas P.
    Wilcox, Shea W.
    Aherne, Noel J.
    ONCOTARGETS AND THERAPY, 2016, 9 : 1635 - 1639
12345